Catalyst Pharmaceuticals price target raised to $24 from $18 at H.C. Wainwright

H.C. Wainwright analyst Andrew Fein raised the firm’s price target on Catalyst Pharmaceuticals to $24 from $18 and keeps a Buy rating on the shares. With the successful platform narrative focused on oral Firdapse commercial execution in the treatment of Lambert Eaton myasthenic syndrome patients, the announced agreement with Eisai for U.S. commercial rights to Fycompa CIII in the treatment of epilepsy "turns a new page" for the Catalyst platform, Fein tells investors in a research note. The analyst incorporated initial estimates for Fycompa.